Novo Nordisk Expands with $1.2B Rare Disease Plant in Denmark, Creating 400 Jobs

Novo Nordisk is making a significant investment in its Odense facility, dedicating 8.5 billion Danish kroner ($1.2 billion) toward the construction of a new 40,000-square-meter plant. This facility is targeted at producing drugs for rare diseases, such as hemophilia, and will create 400 permanent jobs upon its completion in 2027[1][2]. As Novo Nordisk's first new production facility in Denmark in this century, it underscores the company's commitment to expanding its manufacturing capabilities to meet global demand for its medications[1]. The Odense plant is a key part of Novo's strategic expansion, which includes additional plans for a $4.1 billion facility in North Carolina and further investments totaling $6 billion to enhance its overall manufacturing capacity[2].